GSK plc
Tremor tracks 61 of its cancer trials. This is a large company with many drugs, so one trial matters less to it, and company-wide signals count for half.
Company-wide warning signs
These add points to every one of this company's trials.
Trials
- GSKGlaxoSmithKline0Calm
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
Signing up patientsPhase 268 patientsMain results: Mar 16, 2027 - GSKGlaxoSmithKline0Calm
A Study to Investigate Mocertatug Rezetecan as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02)
Signing up patientsPhase 3610 patientsMain results: Jul 23, 2029 - GSKGlaxoSmithKline0Calm
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis
Signing up patientsPhase 260 patientsMain results: Jan 12, 2033 - GSKGlaxoSmithKline0Calm
Mo-Rez in First- Line (1L) Maintenance Treatment of Non-Homologous Recombination Deficient Ovarian Cancer (Non-HRd OC) [BEHOLD-Ovarian03]
Signing up patientsPhase 3720 patientsMain results: Sep 6, 2029 - GSKGlaxoSmithKline0Calm
A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)
Signing up patientsPhase 3600 patientsMain results: Feb 29, 2028 - GSKGlaxoSmithKline0Calm
A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer
Running, no new patientsPhase 241 patientsMain results: Dec 14, 2026 - GSKGlaxoSmithKline0Calm
A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)
Signing up patientsPhase 1/2305 patientsMain results: Jun 21, 2027 - GSKGlaxoSmithKline0Calm
A Study to Evaluate Safety and Clinical Activity of GSK5926371 in Adult Participants With Relapsed or Refractory B-NHL
Signing up patientsPhase 1/249 patientsMain results: Jan 10, 2030 - GSKGlaxoSmithKline0Calm
First-Time-in-Human Study of GSK5471713 in Adults With mCRPC
Signing up patientsPhase 1/254 patientsMain results: Mar 24, 2028 - GSKGlaxoSmithKline0Calm
Extended Access of Momelotinib in Adults With Myelofibrosis
Running, no new patientsPhase 2237 patientsMain results: Dec 11, 2026 - GSKGlaxoSmithKline0Calm
A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)
Signing up patientsPhase 3800 patientsMain results: Aug 30, 2032 - GSKGlaxoSmithKline0Calm
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
Signing up patientsPhase 3420 patientsMain results: Nov 5, 2027 - GSKGlaxoSmithKline0Calm
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
Signing up patientsPhase 1/2346 patientsMain results: Jan 9, 2029 - GSKGlaxoSmithKline0Calm
Two Part (Phase1b/ Phase3) Trial of Subcutaneous Dostarlimab Plus Carboplatin-Paclitaxel in Participants With Primary Advanced or Recurrent Endometrial Cancer
Not started yetPhase 3378 patientsMain results: Nov 5, 2030 - GSKGlaxoSmithKline0Calm
A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)
Signing up patientsPhase 3450 patientsMain results: Jul 22, 2030 - GSKGlaxoSmithKline0Calm
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
Signing up patientsPhase 3450 patientsMain results: May 30, 2028 - GSKGlaxoSmithKline0Calm
A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
Signing up patientsPhase 1/285 patientsMain results: Oct 26, 2027 - GSKGlaxoSmithKline0Calm
A Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) [EMBOLD Prostate-302]
Signing up patientsPhase 3684 patientsMain results: Dec 5, 2029 - GSKGlaxoSmithKline0Calm
A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)
Signing up patientsPhase 1/264 patientsMain results: Nov 5, 2027 - GSKGlaxoSmithKline0Calm
A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and Pimitespib
Signing up patientsPhase 224 patientsMain results: Nov 29, 2027 - GSKGlaxoSmithKline0Calm
A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02)
Signing up patientsPhase 3690 patientsMain results: May 21, 2030 - GSKGlaxoSmithKline0Calm
A Legacy Study in Participants With Gastrointestinal Stromal Tumors (GIST)
Not started yetPhase 272 patientsMain results: Jan 31, 2031 - GSKGlaxoSmithKline0Calm
A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202
Running, no new patientsPhase 2316 patientsMain results: Sep 10, 2026 - GSKGlaxoSmithKline0Calm
A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)
Signing up patientsPhase 1/2184 patientsMain results: Jun 22, 2029 - GSKGlaxoSmithKline0Calm
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
Signing up patientsPhase 1/247 patientsMain results: Sep 28, 2028 - GSKGlaxoSmithKline0Calm
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
Signing up patientsPhase 2200 patientsMain results: Aug 30, 2030 - GSKGlaxoSmithKline0Calm
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Signing up patientsPhase 1/2123 patientsMain results: Aug 3, 2028 - GSKGlaxoSmithKline0Calm
A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally Advanced Rectal Cancer
Not started yetPhase 390 patientsMain results: Dec 12, 2029 - GSKGlaxoSmithKline0Calm
A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)
Running, no new patientsPhase 388 patientsMain results: Jun 30, 2026 - GSKGlaxoSmithKline0Calm
Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Running, no new patientsPhase 3325 patientsMain results: Sep 12, 2022 - GSKGlaxoSmithKline0Calm
Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy
Running, no new patientsPhase 2/3758 patientsMain results: Jun 5, 2025 - GSKGlaxoSmithKline0Calm
Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM
Running, no new patientsPhase 1/214 patientsMain results: Apr 17, 2025 - GSKGlaxoSmithKline0Calm
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM
Running, no new patientsPhase 1/230 patientsMain results: Apr 17, 2025 - GSKGlaxoSmithKline0Calm
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM
Running, no new patientsPhase 1/225 patientsMain results: Apr 17, 2025 - GSKGlaxoSmithKline0Calm
Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Relapsed/Refractory Multiple Myeloma
Not started yetPhase 2150 patientsMain results: Feb 28, 2029 - GSKGlaxoSmithKline0Calm
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
Signing up patientsPhase 237 patientsMain results: Dec 28, 2026 - GSKGlaxoSmithKline0Calm
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer
FinishedPhase 3666 patientsMain results: Feb 26, 2025 - GSKGlaxoSmithKline0Calm
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM
Running, no new patientsPhase 1/220 patientsMain results: Apr 17, 2025 - GSKGlaxoSmithKline0Calm
A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer
Running, no new patientsPhase 2351 patientsMain results: Nov 9, 2026 - GSKGlaxoSmithKline0Calm
All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
Running, no new patientsPhase 321 patientsMain results: May 27, 2024 - GSKGlaxoSmithKline0Calm
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
Running, no new patientsPhase 3302 patientsMain results: Jan 29, 2024 - GSKGlaxoSmithKline0Calm
A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer
Running, no new patientsPhase 2154 patientsMain results: Nov 2, 2026 - GSKGlaxoSmithKline0Calm
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
Signing up patientsPhase 3864 patientsMain results: Jun 30, 2028 - GSKGlaxoSmithKline0Calm
A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer
Signing up patientsPhase 2120 patientsMain results: Nov 23, 2026 - GSKGlaxoSmithKline0Calm
Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Running, no new patientsPhase 1/2208 patientsMain results: Apr 17, 2025 - GSKGlaxoSmithKline0Calm
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM
Running, no new patientsPhase 1/2106 patientsMain results: Apr 17, 2025 - GSKGlaxoSmithKline0Calm
Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma
FinishedPhase 2177 patientsMain results: Aug 19, 2024 - GSKGlaxoSmithKline0Calm
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors
Running, no new patientsPhase 1/242 patientsMain results: Jun 30, 2026 - GSKGlaxoSmithKline0Calm
China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Running, no new patientsPhase 372 patientsMain results: Apr 3, 2024 - GSKGlaxoSmithKline0Calm
Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Running, no new patientsPhase 3494 patientsMain results: Oct 2, 2023 - GSKGlaxoSmithKline0Calm
Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Running, no new patientsPhase 324 patientsMain results: Apr 3, 2024 - GSKGlaxoSmithKline0Calm
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Signing up patientsPhase 3520 patientsMain results: Apr 28, 2031 - GSKGlaxoSmithKline0Calm
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
Running, no new patientsPhase 1/214 patientsMain results: Jun 22, 2026 - GSKGlaxoSmithKline0Calm
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
Signing up patientsPhase 3892 patientsMain results: Mar 19, 2029 - GSKGlaxoSmithKline0Calm
A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)
Signing up patientsPhase 230 patientsMain results: Mar 31, 2030 - GSKGlaxoSmithKline0Calm
A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China
Running, no new patientsPhase 223 patientsMain results: Oct 24, 2027 - GSKGlaxoSmithKline0Calm
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
Running, no new patientsPhase 1/283 patientsMain results: Oct 13, 2026 - GSKGlaxoSmithKline0Calm
Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease
Running, no new patientsPhase 340 patientsMain results: Jun 28, 2024 - GSKGlaxoSmithKline0Calm
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3
FinishedPhase 262 patientsMain results: May 2, 2024 - GSKGlaxoSmithKline0Calm
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)
FinishedPhase 2175 patientsMain results: May 2, 2024 - GSKGlaxoSmithKline0Calm
A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age
FinishedPhase 1/21,080 patientsMain results: Feb 23, 2024
Key executives leaving
From the last 12 months of the company's SEC reports.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
0 sales (0 not pre-planned) · 0 purchases
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.
- None in the last 12 months.